Literature DB >> 16219395

Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A.

Sterghios A Moschos1, Vincent W Bramwell, Satyanarayna Somavarapu, H Oya Alpar.   

Abstract

The characterization of the immunological cascades of the innate immune system activated by pathogen associated molecular patterns (PAMP) recognized by pattern recognition receptors (PRR) have allowed the elucidation of the mechanisms underlying the immunomodulatory properties of adjuvants. Thus, the combinatorial use of adjuvants with specific, complementary functions is investigated to achieve tailored immune responses to subunit vaccines. We have previously shown how combinatorial administration of chitosan and cholera toxin B or muramyl-di-peptide (MDP) intranasally, but not intramuscularly, can allow small doses of MDP which, when administered alone cannot adjuvantise Helicobacter pylori urease (rUre), achieve an immunomodulatory effect through the specific physiological effect of chitosan. The aim of this study was to investigate if in the context of rUre the adjuvantising effect of MDP could be realized via the intramuscular route by combination with aluminium hydroxide, as compared with the routinely used veterinary adjuvant combination of alum and Quil-A. Serum IgG kinetics were comparable between the two adjuvant combination groups. However, the alum + MDP combination afforded higher antigen-specific recall responses in splenocyte cultures, associated with elevated release of the type I immune response cytokines IFN-gamma and IL-2. This data suggests that the adjuvanticity of MDP can be modulated in the context of alum in a manner dissimilar to that of Quil-A, achieving a balancing effect on the responses elicited by alum adjuvantisation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219395     DOI: 10.1016/j.vaccine.2005.09.007

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Protective efficacy of recombinant urease B and aluminum hydroxide against Helicobacter pylori infection in a mouse model.

Authors:  Rodolfo E Bégué; Halina Sadowska-Krowicka
Journal:  FEMS Immunol Med Microbiol       Date:  2010-08-23

2.  Immunogenicity of Recombinant Helicobacter pylori Urease B Administered by Various Routes and with Different Adjuvants.

Authors:  Rodolfo E Bégué; Alyson Moll
Journal:  Open Vaccine J       Date:  2009-01-01

3.  Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.

Authors:  Floris Fransen; Claire J Boog; Jos P van Putten; Peter van der Ley
Journal:  Infect Immun       Date:  2007-10-01       Impact factor: 3.441

4.  Mechanism of immunopotentiation and safety of aluminum adjuvants.

Authors:  Harm Hogenesch
Journal:  Front Immunol       Date:  2013-01-10       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.